A Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2012
At a glance
- Drugs PF-5180999 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 11 Apr 2012 Actual patient number 29 added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.